NCT06297525
Study of STP938 in Advanced Solid Tumours
An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer
Step Pharma, SAS·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Solid Tumor
- Drug/Device/Intervention
- STP938
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Step Pharma, SAS
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Sep 01, 2024
- End date
- May 01, 2027
- Enrollment
- 70 participants
Primary outcome
Safety and Tolerability
Summary
The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy.
 
 The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.
ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06297525
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06297525 through Pure Global AI's free database. This Phase 1 trial is sponsored by Step Pharma, SAS and is currently Not yet recruiting. The study focuses on Solid Tumor. Target enrollment is 70 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.